Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia.

Current oncology (Toronto, Ont.)·2026
Same author

Nanofibrous Bioabsorbable Functionalized Scaffolds Augment Subcutaneous Islet Engraftment and Function in Mice.

Diabetes·2026
Same author

In Vitro Evaluation of Necrostatin-1 Microparticles for Limiting Stress-induced Cell Death and Preserving Islet Function.

Transplantation direct·2026
Same author

Liver Transplantation Following Organ Donation After Medical Assistance in Dying: One Step Further.

Transplantation·2026
Same author

Metformin suppresses β-cell apoptosis under ER stress by inhibiting protein translation.

Metabolism: clinical and experimental·2026
Same author

Pretransplant aerobic exercise improves glycemic outcomes after marginal islet mass transplantation in rats.

American journal of physiology. Endocrinology and metabolism·2026

Related Experiment Video

Updated: May 9, 2026

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice
10:43

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice

Published on: October 31, 2007

Biologic agents in islet transplantation.

Boris Gala-Lopez1, Andrew R Pepper, A M James Shapiro

  • 1Clinical Islet Transplant Program and Department of Surgery, University of Alberta, Edmonton, AB, Canada.

Current Diabetes Reports
|August 7, 2013
PubMed
Summary

Islet transplantation offers hope for managing difficult diabetes, but faces challenges like immune rejection and poor revascularization. Advanced biologic agents are improving graft survival and patient outcomes.

More Related Videos

A Method for Murine Islet Isolation and Subcapsular Kidney Transplantation
17:42

A Method for Murine Islet Isolation and Subcapsular Kidney Transplantation

Published on: April 13, 2011

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice
06:41

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice

Published on: May 10, 2021

Related Experiment Videos

Last Updated: May 9, 2026

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice
10:43

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice

Published on: October 31, 2007

A Method for Murine Islet Isolation and Subcapsular Kidney Transplantation
17:42

A Method for Murine Islet Isolation and Subcapsular Kidney Transplantation

Published on: April 13, 2011

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice
06:41

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice

Published on: May 10, 2021

Area of Science:

  • Endocrinology
  • Immunology
  • Transplantation Biology

Background:

  • Islet transplantation is a viable treatment for select patients with challenging diabetes, particularly those experiencing frequent hypoglycemia or glycemic lability.
  • Despite advancements in islet isolation and preservation, widespread clinical application remains limited due to issues like insufficient revascularization and immune-mediated graft destruction.
  • Preventing alloreactivity and autoimmune recurrence against pancreatic beta cells are critical hurdles in successful islet transplantation.

Observation:

  • Lifelong immunosuppression is currently required for islet transplant recipients.
  • The development of potent and selective biologic agents has markedly reduced acute rejection episodes.
  • These agents have demonstrated efficacy in prolonging islet graft survival and mitigating treatment-related complications.

Findings:

  • Biologic agents play a crucial role in immunosuppressive therapy for islet transplantation, combining induction and maintenance strategies.
  • Historical data shows a progressive integration of these agents into clinical protocols.
  • Current protocols leverage these biologics to enhance engraftment efficiency and long-term graft survival.

Implications:

  • Optimized use of biologic agents is key to improving engraftment and long-term success in clinical islet transplantation.
  • Further research into novel biologic agents may overcome current limitations in islet transplantation.
  • Enhanced immunosuppressive strategies promise better overall outcomes for patients undergoing islet transplantation.